-
Dr. Jian Hou: Treatment of Multiple Myeloma – Coexisting Challenges and Opportunities | The 8th CSCO Hematology Academic Conference
The 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, “Oncology Frontier – Hematology…
-
ASCO 2024 | PostMONARCH Primary Outcomes Released: Abemaciclib + Fulvestrant Continues to Benefit CDK4/6-Pretreated HR+/HER2- Advanced Breast Cancer
PostMONARCH is the first randomized, placebo-controlled phase III study of its kind. At the 2024 ASCO conference, Dr. Kevin Kalinsky from the Winship Cancer Institute of Emory University presented the primary outcomes of the PostMONARCH study, revealing that continued treatment with abemaciclib (Abemaciclib) + fulvestrant benefits patients even after progression on CDK4/6 inhibitor therapy. This…
-
EHA Global Insights | Dr. Michael Wang Interprets the Latest Results from the ECHO Clinical Trial
Mantle cell lymphoma (MCL) is an aggressive lymphoma with high malignancy and poor treatment outcomes, especially for elderly patients or those in poor health. Optimizing treatment regimens for these patient groups is crucial. At the recent 29th European Hematology Association (EHA) annual meeting, Dr. Michael Wang from University of Texas MD Anderson, Houston, USA presented…
-
The Chinese Influence at EHA: Dr. He Huang’s Team Presents Multiple Studies, Offering New Insights into Bone Marrow Transplantation and CAR-T Therapy
The 29th European Hematology Association (EHA) Annual Meeting was successfully held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it annually attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research…
-
EHA 2024丨Bright Future Ahead: Key Developments in Luspatercept Treatment for Lower-Risk MDS Interpreted by Dr. Chungkang Chang
The European Hematology Association (EHA) annual meeting, one of the most influential international academic conferences in the field of hematology, gathers numerous experts and scholars worldwide every year. The aim is to share and deeply discuss innovative ideas and the latest scientific and clinical research advancements in hematology, thereby promoting continuous progress in the field.…
-
Dr. Libo Zhao: Advances in TDM Practices for Anti-Infective Drugs at Home and Abroad丨IDSC 2024
Editor’s Note: Antimicrobial drugs play a crucial role in clinical treatment, essential for controlling infectious diseases caused by various pathogens, including bacteria, mycoplasma, and chlamydia. However, inappropriate use of these…
-
Dr. Baiyi Chen: Key Elements in Early Empirical Treatment of Invasive Candidiasis
Editor’s Note: Candidiasis presents with a wide range of clinical manifestations, among which invasive candidiasis poses significant risks, leading to longer hospital stays, increased healthcare costs, and higher mortality rates.…
-
Dr. Sujun Zheng: Advances in the Diagnosis and Treatment of Inactive HBsAg Carriers
According to estimates from the Polaris Observatory, the prevalence of inactive hepatitis B surface antigen (HBsAg) carriers in the general population in China was 6.1% in 2016, with approximately 86 million people chronically infected with HBV. This suggests that around 36.08% of these individuals are inactive HBsAg carriers (IHC), equating to about 30.96 million people.…
Connecting Medical Expertise through Media